UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

Filed b	y the R	egistrant 🗵
Filed by a Party other than the Registrant \Box		
Check	the app	propriate box:
	Preliminary Proxy Statement	
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))	
	Definitive Proxy Statement	
\boxtimes	Definitive Additional Materials	
	Soliciting Material Pursuant to §240.14a-12	
		KALA PHARMACEUTICALS, INC. (Name of Registrant as Specified in Its Charter)
	(1	Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):		
\times	No fee required.	
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.	
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
	Fee paid previously with preliminary materials.	
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.	
	(1)	Amount previously paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:

*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 25, 2020

KALA PHARMACEUTICALS, INC.

Meeting Information

Meeting Type: Annual Meeting For holders as of: April 27, 2020

Date: June 25, 2020 **Time:** 9:00 AM EDT

Location: Kala Pharmaceuticals, Inc.

490 Arsenal Way, Suite 120 Watertown, MA 02472

or by means of remote communication, in which case we will announce such decision and how to participate

You are receiving this communication because you hold shares in the above named company.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

490 ARESENAL WAY, SUITE 120 WATERTOWN, MA 02472

Before You Vote -

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

I. Annual Report 2. Notice & Proxy Stateme

How to View Online:
Have the information that is printed in the box marked by the arrow | xxxx xxxx xxxx xxxx xxxx | (located on the following page) and visit: www.proxyvote.com

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET: www.proxyvote.com
2) BY E-MAIL*: sendmaterial@proxyvote.com
* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow $\longrightarrow \boxed{XXXX XXXX XXXX XXXX}$ (located on the following page) in the subject line. Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment

advisor. Please make the request as instructed above on or before June 11, 2020 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow $\rightarrow xxxxxxxxxxxxxxxxxxx$ available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

R1.0.1.18 0000464973_2

Voting items
The Board of Directors recommends you vote
FOR the following Class III director
nominees to serve until the 2023 Annual
Meeting of Stockholders:

1. Election of three Class III Directors

01) Robert Paull

02) Howard B. Rosen

03) Rajeev Shah

The Board of Directors recommends you vote FOR the following proposals:

- To ratify the appointment of Deloitte & Touche LLP as Kala Pharmaceuticals, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2020.
- 3. The approval of an amendment to the 2017 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder.

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

Due to concerns relating to the public health impact of the coronavirus outbreak (COVID-19) and related travel, the 2020 Annual Meeting may be held by means of remote communication (i.e., a virtual-only meeting). If this is determined, we will announce the decision in advance, and will provide details on how to participate at www.kalarx.com. If you are planning to attend our Annual Meeting, please check the website in the days leading up to the meeting date. As always, we encourage you to vote your shares prior to the Annual Meeting regardless of whether you intend to attend in person.

0000464973 3